Next Article in Journal
Gender-Related Approach to Kidney Cancer Management: Moving Forward
Next Article in Special Issue
Inflammatory and Oxidative Stress Markers—Mirror Tools in Rheumatoid Arthritis
Previous Article in Journal
SERS-Based Biosensors for Virus Determination with Oligonucleotides as Recognition Elements
Previous Article in Special Issue
Signaling Pathways Potentially Responsible for Foam Cell Formation: Cholesterol Accumulation or Inflammatory Response—What is First?
Review

SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment

1
Systemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, Italy
2
Unit of Internal Medicine, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(9), 3377; https://doi.org/10.3390/ijms21093377
Received: 23 April 2020 / Revised: 6 May 2020 / Accepted: 7 May 2020 / Published: 10 May 2020
(This article belongs to the Special Issue Immunoglobulins in Inflammation)
The current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of its highly contagious nature, the great number of patients requiring intensive care therapy, and the high fatality rate. In the absence of specific antiviral drugs, passive prophylaxis, or a vaccine, the treatment aim in these patients is to prevent the potent virus-induced inflammatory stimuli from leading to the acute respiratory distress syndrome (ARDS), which has a severe prognosis. Here, the mechanism of action and the rationale for employing immunological strategies, which range from traditional chemically synthesized drugs, anti-cytokine antibodies, human immunoglobulin for intravenous use, to vaccines, are reviewed. View Full-Text
Keywords: anti-cytokine antibodies; human immunoglobulin for intravenous use; COVID-19; SARS-CoV-2; inflammation; acute respiratory syndrome; immune system targeting in COVID-19 anti-cytokine antibodies; human immunoglobulin for intravenous use; COVID-19; SARS-CoV-2; inflammation; acute respiratory syndrome; immune system targeting in COVID-19
MDPI and ACS Style

Prete, M.; Favoino, E.; Catacchio, G.; Racanelli, V.; Perosa, F. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment. Int. J. Mol. Sci. 2020, 21, 3377. https://doi.org/10.3390/ijms21093377

AMA Style

Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment. International Journal of Molecular Sciences. 2020; 21(9):3377. https://doi.org/10.3390/ijms21093377

Chicago/Turabian Style

Prete, Marcella, Elvira Favoino, Giacomo Catacchio, Vito Racanelli, and Federico Perosa. 2020. "SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment" International Journal of Molecular Sciences 21, no. 9: 3377. https://doi.org/10.3390/ijms21093377

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop